Validation of the anti-inflammatory properties of small-molecule IκB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle

Molecular Pharmacology

Volumn 70, Issue 2, 2006, Pages 697-705

  Catley, Matthew C ^a   Sukkar, Maria B ^a   Chung, K Fan ^a   Jaffee, Bruce ^b   Liao, Sha Mei ^b   Coyle, Anthony J ^b   Haddad, El Bdaoui ^c   Barnes, Peter J ^a   Newton, Robert ^d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c SANOFI   (France)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; CYCLOOXYGENASE 2; DEXAMETHASONE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH REGULATED ONCOGENE ALPHA; I KAPPA B KINASE; I KAPPA B KINASE 2; I KAPPA B KINASE 3; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; ML 120B; MONOCYTE CHEMOTACTIC PROTEIN 1; N (6 CHLORO 7 METHOXY 9H BETA CARBOLIN 8 YL) 2 METHYLNICOTINAMIDE; N (6 CHLORO 9H BETA CARBOLIN 8 YL) NICOTINAMIDE; ONCOPROTEIN; RANTES; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE; VALIDATION PROCESS;

ADENOVIRIDAE; ANTI-INFLAMMATORY AGENTS; BRONCHI; CELL SURVIVAL; CELLS, CULTURED; DEXAMETHASONE; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; I-KAPPA B KINASE; INTERCELLULAR ADHESION MOLECULE-1; MUSCLE, SMOOTH; NF-KAPPA B; PROTEIN KINASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746217403     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.023150     Document Type: Article

References (35)

1. Adcock IM and Ito K (2004) Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue? Curr Opin Pharmacol 4:257-262.
2. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208.
3. Ammit AJ, Lazaar AL, Irani C, O'Neill GM, Gordon ND, Amrani Y, Penn RB, and Panettieri RA Jr (2002) Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth muscle cells: modulation by glucocorticoids and beta-agonists. Am J Respir Cell Mol Biol 26:465-474.
4. Barnes PJ (2004) New drugs for asthma. Nat Rev Drug Discov 3:831-844.
5. Barnes PJ and Hansel TT (2004) Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364:985-996.
6. Barnes PJ and Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
7. Belvisi MG, Saunders MA, Haddad E, Hirst SJ, Yacoub MH, Barnes PJ, and Mitchell JA (1997) Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type. Br J Pharmacol 120:910-916.
8. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, and Adams J (2003) Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13:2419-2422.
9. Catley MC, Cambridge LM, Nasuhara Y, Ito K, Chivers JE, Beaton A, Holden NS, Bergmann MW, Barnes PJ, and Newton R (2004) Inhibitors of protein kinase C (PKC) prevent activated transcription: role of events downstream of NF-κB DNA binding. J Biol Chem 279:18457-18466.
10. Catley MC, Chivers JE, Cambridge LM, Holden N, Slater DM, Staples KJ, Bergmann MW, Loser P, Barnes PJ, and Newton R (2003) IL-1beta-dependent activation of NF-kappaB mediates PGE2 release via the expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. FEBS Lett 547:75-79.
11. Catley MC, Chivers JE, Holden NS, Barnes PJ, and Newton R (2005) Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br J Pharmacol 145:114-122.
12. Clarke DL, Belvisi MG, Catley MC, Yacoub MH, Newton R, and Giembycz MA (2004) Identification in human airways smooth muscle cells of the prostanoid receptor and signalling pathway through which PGE2 inhibits the release of GM-CSF. Br J Pharmacol 141:1141-1150.
13. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, and Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701.
14. Hayden MS and Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195-2224.
15. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647.
16. Holden NS, Catley MC, Cambridge LM, Barnes PJ, and Newton R (2004) ICAM-1 expression is highly NF-kappaB-dependent in A549 cells. No role for ERK and P38 MAPK. Eur J Biochem 271:785-791.
17. Howarth PH, Knox AJ, Amrani Y, Tliba O, Panettieri RA Jr, and Johnson M (2004) Synthetic responses in airway smooth muscle. J Allergy Clin Immunol 114:S32-S50.
18. Jawien J (2002) A new insight into aspirin-induced asthma. Eur J Clin Investig 32:134-138.
19. Karin M, Yamamoto Y, and Wang QM (2004) The IKK NF-kappaB system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26.
20. Krappmann D, Wulczyn FG, and Scheidereit C (1996) Different mechanisms control signal-induced degradation and basal turnover of the NF-kappaB inhibitor IkappaB alpha in vivo. EMBO (Eur Mol Biol Organ) J 15:6716-6726.
21. Lawrence T, Bebien M, Liu GY, Nizet V, and Karin M (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (Lond) 434:1138-1143.
22. 2 and fenoterol. Eur J Pharmacol 433:231-235.
23. Li Q and Verma IM (2002) NF-KappaB regulation in the immune system. Nat Rev Immunol 2:725-734.
24. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, et al. (2006) Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 107:4266-4273.
25. Nasuhara Y, Adcock IM, Catley M, Barnes PJ, and Newton R (1999) Differential IκB kinase activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells. Evidence for additional regulatory steps in κB-dependent transcription. J Biol Chem 274:19965-19972.
26. Newton R, Staples KJ, Hart L, Barnes PJ, and Bergmann MW (2001) GM-CSF expression in pulmonary epithelial cells is regulated negatively by posttranscriptional mechanisms. Biochem Biophys Res Commun 287:249-253.
27. Newton R, Stevens DA, Hart LA, Lindsay M, Adcock IM, and Barnes PJ (1997) Superinduction of COX-2 MRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett 418:135-138.
28. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
29. Pang L and Knox AJ (1997) Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclo-oxygenase-2 in cultured human airway smooth muscle cells. Br J Pharmacol 121:579-587.
30. Sukkar MB, Issa R, Xie S, Oltmanns U, Newton R, and Chung KF (2004) Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-gamma and TNF-alpha and regulation by TGF-beta and corticosteroids. Am J Physiol 287:L1230-L1240.
31. Traves SL, Culpitt SV, Russell RE, Barnes PJ, and Donnelly LE (2002) Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 57:590-595.
32. Traves SL, Smith SJ, Barnes PJ, and Donnelly LE (2004) Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 76:441-450.
33. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, et al. (2006) A selective small molecule IKKβ inhibitor blocks NF-κB mediated inflammatory responses in human fibroblast like synoviocytes, chondrocytes and mast cells. J Pharmacol Exp Ther 317:989-1001.
34. Wouters EF (2004) Management of severe COPD. Lancet 364:883-895.
35. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, and Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-KappaB activation. Cell 91:243-252.